THE HAGUE, July 27 (Xinhua) -- Dutch health technology company Royal Philips on Monday reported second-quarter sales of 4.4 billion euros (5 billion U.S. dollars), up 4 percent year on year, driven by growth across all of its business segments.
Comparable sales in "diagnosis and treatment" increased by 2 percent, while "connected care" rose by 2 percent and "personal health" posted a growth of 8 percent.
Meanwhile, income from operations reached 609 million euros (692.52 million dollars), including a 186 million-euro (211.51 million-dollar) benefit from a U.S. tariff refund.
"We largely completed the U.S. tariff refund process during the quarter and continue to actively manage the broader macro environment, including inflation," Royal Philips CEO Roy Jakob said.
Philips reiterated its full-year 2026 outlook, updated to reflect the benefit from the U.S. tariff refund. The company expects comparable sales growth of 3 percent to 4.5 percent for the year.
Earlier this month, the Dutch government announced a 10-year investment plan for the country's medical technology sector, saying that public investment would be matched by private investment. As part of the initiative, Philips has pledged to invest 50 million euros (56.86 million dollars), with a focus on advancing AI- and robotics-assisted image-guided therapies.
